Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Schellens

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Anti-Cancer Drugs|August 7, 2001
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxelM M Malingré, W W Ten Bokkel Huinink, K Duchin, et al.
British Journal of Cancer|May 1, 1994
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusionJ Ma, J Verweij, H J Kolker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Limited sampling models for topotecan pharmacokineticsL J van Warmerdam, J Verweij, H Rosing, et al.
Journal of Neuro-Oncology|July 27, 1999
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administrationC S Straathof, M J van den Bent, W J Loos, et al.
Clinical Pharmacology and Therapeutics|June 29, 2000
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methodsA D Huitema, R A Mathôt, M M Tibben, et al.
Anti-Cancer Drugs|October 19, 2000
The clinical pharmacology of alkylating agents in high-dose chemotherapyA D Huitema, K D Smits, R A Mathôt, et al.
Lancet (London, England)|August 5, 1998
Co-administration of cyclosporin enables oral therapy with paclitaxelJ M Meerum Terwogt, J H Beijnen, W W ten Bokkel Huinink, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2001
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolitesT Kerbusch, R A Mathôt, H J Keizer, et al.
Anti-Cancer Drugs|January 6, 2001
Pharmaceutical development of anticancer agents derived from marine sourcesB Nuijen, M Bouma, C Manada, et al.
Anti-Cancer Drugs|August 7, 2001
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide FR W Sparidans, E Stokvis, J M Jimeno, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Anti-Cancer Drugs|August 7, 2001
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxelM M Malingré, W W Ten Bokkel Huinink, K Duchin, et al.
British Journal of Cancer|May 1, 1994
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusionJ Ma, J Verweij, H J Kolker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Limited sampling models for topotecan pharmacokineticsL J van Warmerdam, J Verweij, H Rosing, et al.
Journal of Neuro-Oncology|July 27, 1999
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administrationC S Straathof, M J van den Bent, W J Loos, et al.
Clinical Pharmacology and Therapeutics|June 29, 2000
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methodsA D Huitema, R A Mathôt, M M Tibben, et al.
Anti-Cancer Drugs|October 19, 2000
The clinical pharmacology of alkylating agents in high-dose chemotherapyA D Huitema, K D Smits, R A Mathôt, et al.
Lancet (London, England)|August 5, 1998
Co-administration of cyclosporin enables oral therapy with paclitaxelJ M Meerum Terwogt, J H Beijnen, W W ten Bokkel Huinink, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2001
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolitesT Kerbusch, R A Mathôt, H J Keizer, et al.
Anti-Cancer Drugs|January 6, 2001
Pharmaceutical development of anticancer agents derived from marine sourcesB Nuijen, M Bouma, C Manada, et al.
Anti-Cancer Drugs|August 7, 2001
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide FR W Sparidans, E Stokvis, J M Jimeno, et al.
Pageof 14